Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 clearance during supplementation in CKD
NCT03576716Phase 1Completed
- Sponsor
- University of Washington
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of d6-25-hydroxyvitamin D3 in chronic kidney disease (CKD), sponsored by University of Washington. Primary endpoint: Metabolic Clearance of D6-25(OH)D3 at 6 months. Started Jun 2018; status: completed.
02
Drugs
d6-25-hydroxyvitamin D3
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03576716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576716.